Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 7/20 | 0.58 |
| ▸ | NOS1 | P29475 | 2/20 | 0.58 |
| ▸ | NOS3 | P29474 | 1/20 | 0.58 |
| ▸ | NOS2 | P35228 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SLC11A2 | P49281 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1140195 | 0.83 | IDO1 (0.61) | IDO1NOS1NOS3NOS2TDP1 | |
| SCHEMBL162537 | 0.83 | CA12 (0.63) | IDO1NOS1NOS3NOS2TDP1 | |
| SCHEMBL7871370 | 0.81 | IDO1 (0.54) | IDO1NOS1NOS3NOS2TDP1 | |
| Hydrochloric Acid SCHEMBL5506584 | 0.81 | IDO1 (0.63) | IDO1NOS1NOS3NOS2TDP1 | |
| SCHEMBL12349707 | 0.81 | IDO1 (0.54) | IDO1NOS1NOS3NOS2TDP1 | |
| Bromide SCHEMBL1244857 | 0.81 | IDO1 (0.63) | IDO1NOS1NOS3NOS2TDP1 | |
| SCHEMBL42484 | 0.81 | IDO1 (0.54) | IDO1NOS1NOS3NOS2TDP1 | |
| Bromide SCHEMBL8425388 | 0.79 | IDO1 (0.52) | IDO1NOS1NOS3NOS2TDP1 | |
| SCHEMBL7277542 | 0.78 | IDO1 (0.50) | IDO1NOS1NOS3NOS2TDP1 | |
| SCHEMBL5827235 | 0.78 | IDO1 (0.50) | IDO1NOS1NOS3NOS2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2069291-B1 | HDAC INHIBITORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2017-12-20 | — | — | EP | claimed |
| EP-2864318-B1 | 2-AMINOPYRAZINE DERIVATIVES AS CSF-1R KINASE INHIBITORS | MACROPHAGE PHARMA LTD (GB) | 2017-08-09 | — | — | EP | claimed |
| US-9725407-B2 | HDAC inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-08 | — | — | US | claimed |
| CN-104151200-B | Hdac inhibitor | 葛兰素史克知识产权发展有限公司 | 2017-06-20 | — | — | CN | claimed |
| US-20160137594-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2016-05-19 | — | — | US | claimed |
| US-9133104-B2 | Enzyme inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2015-09-15 | — | — | US | claimed |
| US-20150126534-A1 | ENZYME AND RECEPTOR MODULATION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-05-07 | — | — | US | claimed |
| US-8962825-B2 | Hydroxamates as inhibitors of histone deacetylase | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-02-24 | — | — | US | claimed |
| CN-104151200-A | Hdac inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENTLTD | 2014-11-19 | — | — | CN | claimed |
| CN-101528677-B | Hdac inhibitors | GSK IP DEV CORP | 2014-07-30 | — | — | CN | claimed |
| WO-1997003783-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1997-02-06 | — | — | WO | claimed |
| CN-1138851-A | Metalloproteinase inhibitors | BRITISH BIOTECH PHARM (GB) | 1996-12-25 | — | — | CN | claimed |
| EP-0740652-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-11-06 | — | — | EP | claimed |
| EP-0740655-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-11-06 | — | — | EP | claimed |
| WO-1996033165-A1 | DERIVATIVES OF SUCCINAMIDE AND THEIR USE AS METALLOPROTEINASE INHIBITOR | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-10-24 | — | — | WO | claimed |
| WO-1996033161-A1 | DERIVATIVES OF SUCCINAMIDE AND THEIR USE AS METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1996-10-24 | — | — | WO | claimed |
| WO-1995035275-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-12-28 | — | — | WO | claimed |
| WO-1995032944-A1 | SUCCINYL HYDROXAMIC ACID, N-FORMYL-N-HYDROXY AMINO CARBOXYLIC ACID AND SUCCINIC ACID AMIDE DERIVATIVES AS METALLOPROTEASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-12-07 | — | — | WO | claimed |
| WO-1995019961-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | claimed |
| WO-1995019956-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1995-07-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137594-A1 | HDAC INHIBITORS | HDAC1, HDAC11, HDAC2 | IDO1 528/4885NOS1 662/4885NOS3 1260/4885 |
| US-20150126534-A1 | ENZYME AND RECEPTOR MODULATION | CES1, HCAR1, DNPEP | IDO1 3015/4885NOS1 3326/4885NOS3 3766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.